Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 197Leukemia 110Lymphoma 90Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Burkitt Lymphoma 52Myelodysplastic Syndromes 47Lymphoma, Mantle-Cell 47Lymphoma, Large B-Cell, Diffuse 47Lymphoma, Non-Hodgkin 46Leukemia, Myelomonocytic, Acute 30Lymphoma, Follicular 29Leukemia, Monocytic, Acute 29Recurrence 25Congenital Abnormalities 25Leukemia, Erythroblastic, Acute 24Lymphoma, Large-Cell, Immunoblastic 23Leukemia, Megakaryoblastic, Acute 23Blast Crisis 21Hodgkin Disease 20Leukemia, Lymphocytic, Chronic, B-Cell 18Leukemia, Myelomonocytic, Chronic 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Lymphoma, B-Cell, Marginal Zone 15Anemia, Refractory, with Excess of Blasts 15Leukemia, Myeloid, Accelerated Phase 13Leukemia, Biphenotypic, Acute 13Leukemia, Myeloid, Chronic-Phase 12Dendritic Cell Sarcoma, Interdigitating 12Myeloproliferative Disorders 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10

Interventions

Trastuzumab 5Carboplatin 4toripalimab 2pertuzumab 2pembrolizumab 2Tretinoin 2Paclitaxel 2Immunotherapy 2Drug Therapy 2Doxorubicin 2Docetaxel 2Cytarabine 2130-nm albumin-bound paclitaxel 2zanidatamab 1venetoclax 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1tislelizumab 1temsirolimus 1talazoparib 1tagraxofusp 1sarilumab 1sargramostim 1pyrotinib 1pexidartinib 1pazopanib 1patritumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Pathologic Complete Response × Cytarabine × Clear all
NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Nanfang Hospital, Southern Medical University

Phase 2 Unknown
100 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT01843179 2017-02-17

Sulindac for Patients With AML

Massachusetts General Hospital

Phase 2 Withdrawn
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡